A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.

Clinical trial NCT00171145 · COMPLETED

Trial details

NCT number: NCT00171145
Sponsor: Novartis
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Overactive Bladder Syndrome

Start date: 2004-04-01
Enrollment: 445

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.